From theheart.org on Medscape

Coverage from the

American Heart Association (AHA) Scientific Sessions 2019

November 16 - 18, 2019; Philadelphia, Pennsylvania

November 16 - 18, 2019 Philadelphia, Pennsylvania

AHA 2019 Silencing Novel Target Genes: A New Strategy for Lipid Lowering Following in the footsteps of inclisiran, two lipid-lowering therapies based on silencing specific genes involved in lipid metabolism showed promising preliminary results in initial clinical trials.
Medscape Medical News, November 19, 2019
AHA 2019 DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family 'What I don't want to see is slow uptake, once it gets the indication in nondiabetics,' said one physician. Think of SGLT2 inhibitors the same way as ACE inhibitors, beta blockers, and other HF drugs.
Medscape Medical News, November 19, 2019
AHA 2019 ISCHEMIA: PCI, Surgery Strike Out vs Meds The $100 million trial signals that not every stable patient with stable, moderate-to-severe ischemic disease needs to go to the cath lab, and will not suffer as a result.
Medscape Medical News, November 16, 2019

Meeting Highlights At A Glance

Top News From AHA 2019: Slideshow Results of the highly anticipated ISCHEMIA trial testing the true value of an early invasive strategy in stable ischemic heart disease was the breakout star of this year's scientific sessions.

Conference News

AHA 2019 Canagliflozin Helps Heart, Kidneys in 'Well-Controlled' Diabetes
Medscape Medical News, December 9, 2019
AHA 2019 Cardiotwitter Takes the ISCHEMIA Study to Heart
Medscape Medical News, December 6, 2019
AHA 2019 Vernakalant Safe, Effective in Lead-up to FDA Panel Review
Medscape Medical News, December 3, 2019
AHA 2019 Cath Lab Exercise Test Flags Coronary Microvascular Dysfunction
Medscape Medical News, November 28, 2019
AHA 2019 Calls Grow Louder to Regionalize Congenital Heart Surgery
Medscape Medical News, November 27, 2019
AHA 2019 Unmet LDL-C Goals Common in ASCVD: PINNACLE, NHANES
Medscape Medical News, November 26, 2019
AHA 2019 Impella Bleeding, Mortality 'Signals' in MI-Shock, High-Risk PCI
Medscape Medical News, November 26, 2019
AHA 2019 BETonMACE: Negative Trial, but 'Cautious Optimism' on Apabetalone
Medscape Medical News, November 26, 2019
AHA 2019 FUEL: Udenafil Improves Exercise Capacity After Fontan Surgery
Medscape Medical News, November 26, 2019
AHA 2019 French Studies Point to Inherent Differences in TAVR Valves
Medscape Medical News, November 25, 2019
AHA 2019 DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
Medscape Medical News, November 25, 2019
AHA 2019 Treating LDL to Below 70 Reduces Recurrent Stroke
Medscape Medical News, November 21, 2019
AHA 2019 Silencing Novel Target Genes: A New Strategy for Lipid Lowering
Medscape Medical News, November 19, 2019
AHA 2019 DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family
Medscape Medical News, November 19, 2019
AHA 2019 COACT at 1 Year: Later Angiography Okay in Non-STEMI Cardiac Arrest
Medscape Medical News, November 19, 2019
AHA 2019 RECOVERY: Early Surgery Best in Severe Asymptomatic AS?
Medscape Medical News, November 19, 2019
AHA 2019 EVAPORATE: Early Mechanistic Clues to Vascepa's CV Benefits
Medscape Medical News, November 19, 2019

AHA 2019 ORION-9: 50% LDL Reduction With Inclisiran in FH Patients
Medscape Medical News, November 18, 2019
AHA 2019 GALILEO, GALILEO 4D: Mixed Results in Post-TAVR Anticoagulation
Medscape Medical News, November 18, 2019
AHA 2019 Colchicine Before PCI Cuts Inflammatory Markers but Not MACE
Medscape Medical News, November 17, 2019
AHA 2019 Ticagrelor Monotherapy Affirmed in High-Risk ACS: TWILIGHT-ACS
Medscape Medical News, November 17, 2019
AHA 2019 Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF
Medscape Medical News, November 17, 2019
AHA 2019 ISCHEMIA-CKD: No Gain From Initial Invasive Strategy
Medscape Medical News, November 17, 2019
AHA 2019 ISCHEMIA: PCI, Surgery Strike Out vs Meds
Medscape Medical News, November 16, 2019
AHA 2019 ORION-10: 58% Reduction in LDL With Inclisiran
Medscape Medical News, November 16, 2019
AHA 2019 AHA Invests Big in 'End the Lies' Research to Thwart Youth Vaping
Medscape Medical News, November 16, 2019
AHA 2019 COLCOT: Colchicine Shows Promise to Reduce Events After MI
Medscape Medical News, November 16, 2019
AHA 2019 Interim ISCHEMIA Analysis: Uphill Fight to Hit Treatment Targets
Medscape Medical News, November 15, 2019
AHA 2019 Meth-Related HF Worse, Responds Well to Meds if Abuse Stops
Medscape Medical News, November 14, 2019
AHA 2019 Generic Valsartan Abandoned After Recalls, ED Visits Rise
Medscape Medical News, November 13, 2019
AHA 2019 Marijuana Use Linked to Stroke, Arrhythmia in Young People
Medscape Medical News, November 12, 2019
AHA 2019 Fears of Legal Risk From Bystander CPR Are Overblown
Medscape Medical News, November 11, 2019
AHA 2019 AHA 2019: ISCHEMIA Trial a Moment of Truth for PCI?
Medscape Medical News, November 8, 2019

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

TAVR Valves Compared, and Other Lessons on the Management of AS
Walid Amara, MD; Eric Van Belle, MD
Could Colchicine Be the New Aspirin?
Jean-Claude Tardif, MD; Michel Zétouni, MD, MSc
Controversies in Cardiogenic Shock
Ileana L. Piña, MD, MPH
Impella vs IABP: Urgent Need for RCT
John M. Mandrola, MD; Sanket S. Dhruva, MD, MHS; Nihar R. Desai, MD, MPH
Making Room for New Drugs for Heart Failure
Ileana L. Piña, MD, MPH; Mary Norine Walsh, MD
ISCHEMIA-CKD PI Hopes Study Doesn't Fuel the Flames of Renalism
Interviewer: Tricia Ward; Interviewee: Sripal Bangalore, MD, MHA
Managing the SIHD Patient in a Post-ISCHEMIA World
Michelle L. O'Donoghue, MD, MPH; Rasha Al-Lamee, MBBS, MA, PhD ; Jacqueline E. Tamis-Holland, MD
John Spertus, MD, on the Practice-Changing ISCHEMIA Trial
Interviewer: Bruce Jancin; Interviewee: John A. Spertus, MD, MPH

Bloggers From The Floor

Signal of Harm From Impella Has an Easy Answer Two independent observational studies find worse outcomes with the Impella device compared with intra-aortic balloon pump. The time for a randomized controlled trial is now, says John Mandrola, MD.
The ISCHEMIA Trial -- Cardiology Changes Today The AHA late-breaking trial comparing an invasive vs medical strategy for patients with stable ischemic disease validates Nobel prize-winning medical conservative Bernard Lown, writes John Mandrola, MD.
Mandrola Previews 2019 AHA and the ISCHEMIA Trial All eyes will be on ISCHEMIA in Philadelphia, but a study on asymptomatic aortic stenosis as well as trials in heart failure and cardiogenic shock also piqued Dr John Mandrola's interest.